PB2111: SUBGROUP ANALYSIS IN RE-MIND2, AN OBSERVATIONAL, RETROSPECTIVE COHORT STUDY OF TAFASITAMAB + LENALIDOMIDE VERSUS SYSTEMIC THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

• G. S. Nowakowski,
• D. H. Yoon,
• E. Joffe,
• P. L. Zinzani,
• L. Sabatelli,
• E. E. Waltl,
• C. G. Alvero,
• G. Hess,
• P. Riedell,
• K. Kim,
• D. Brixner,
• G. Salles

Affiliations

G. S. Nowakowski

1 Division of Hematology, Mayo Clinic, Rochester, United States of America

D. H. Yoon

2 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

E. Joffe

3 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States of America

P. L. Zinzani

4 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli

L. Sabatelli

6 Incyte Biosciences International Sàrl, Morges, Switzerland

E. E. Waltl

7 MorphoSys AG, Planegg, Germany

C. G. Alvero

8 MorphoSys US Inc., Boston, United States of America

G. Hess

9 Department of Hematology, Oncology and Pneumology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany

P. Riedell

10 Division of Hematology and Oncology, University of Chicago Medicine, Chicago

K. Kim

11 Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake

D. Brixner

13 Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, United States of America

G. Salles

3 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States of America